Mark Avagliano
2021
In 2021, Mark Avagliano earned a total compensation of $1.5M as Chief Business Officer at G1 Therapeutics, a 5% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $150,232 |
|---|---|
| Option Awards | $706,887 |
| Salary | $447,120 |
| Stock Awards | $198,770 |
| Other | $8,700 |
| Total | $1,511,709 |
Avagliano received $706.9K in option awards, accounting for 47% of the total pay in 2021.
Avagliano also received $150.2K in non-equity incentive plan, $447.1K in salary, $198.8K in stock awards and $8.7K in other compensation.
Rankings
In 2021, Mark Avagliano's compensation ranked 7,228th out of 12,415 executives tracked by ExecPay. In other words, Avagliano earned more than 41.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,228 out of 12,415 | 42nd |
Division Manufacturing | 3,170 out of 5,505 | 42nd |
Major group Chemicals And Allied Products | 1,401 out of 2,375 | 41st |
Industry group Drugs | 1,248 out of 2,096 | 41st |
Industry Pharmaceutical Preparations | 916 out of 1,546 | 41st |
Source: SEC filing on April 26, 2023.
Avagliano's colleagues
We found two more compensation records of executives who worked with Mark Avagliano at G1 Therapeutics in 2021.